dual agonist glp-1 glucagon New strategies for the treatment of obesity and metabolic dysfunctions The Emerging Role of Dual

doi:10.1007/s11095-012-0917-z 179

gave 3731 non-diabetics with a BMI of 27 kg/m2 or 30 kg/m2 3 mg of Liraglutide subcutaneously once a day

That one-two punch promotes stable blood sugar levels

liraglutide significantly decreased body fat and waist-to-hip ratio (p=0.003), and exenatide reduced waist-to-hip ratio but had minimal weight loss benefits.[6] In the STEP1 study, adults with obesity without diabetes receiving semaglutide 2.4mg plus lifestyle interventions had a mean weight loss of 14.9% from baseline in addition to improved fasting glucose and lipids, increased physical activity, and decreased fat mass.[7] The SURMOUNT-1 trial demonstrated that tirzepatide 5mg, 10mg, and 15mg caused significant improvement in weight, total body fat mass, lipids, systolic and diastolic blood pressure, and fasting insulin levels.[5] Cardiovascular disease risk reduction Diabetes represents a major risk factor for cardiovascular disease

Clinical applications in cardiovascular disease prevention Recent American College of Cardiology/American Heart Association guidelines advocate for the use of GLP-1RAs in patients with T2DM at high risk of atherosclerotic cardiovascular disease (ASCVD), irrespective of well-controlled glucose levels, based on the clinical trials mandated by FDA-issued industry guidelines in December 2008 to assess the cardiovascular effects of new diabetic therapies (247)

Qiu C, Wang YP, Pan XD, Liu XY, Chen Z, Liu LB